Taken together, these results demonstrate that our senolytic HTS identified a compound that preferentially targets p16Ink4a+ fibroblasts from fibrotic lungs, which was subsequently validated in vivo and ex vivo in mouse models of lung fibrosis and human IPF samples, respectively. This evidence concerns the gene CDKN2A and idiopathic pulmonary fibrosis.